Reinventing Therapeutics Through Chemical Genomics	site map japanese

top > Drug Discovery > Reverse targeting

Drug Discovery : Reverse Targeting

Aphoenix's approach for drug discovery is called "reverse targeting," of small molecules. Aphoenix exploits drugs or other biologically active compounds with unknown mechanisms of action as probes for discovering valid and druggable targets using its proprietary bead-based affinity chromatographic techniques and then uses these targets to generate novel therapeutics.

	-	Aphoenix takes existing drugs and drug-like molecules without MOA to identify binding proteins in cell using proprietary SG beads
	-	Drug binders are analyzed with Aphoenix's state-of-art informatics and then analyzed its functions in vitro/vivo for the "partial" target validation
	-	Aphoenix does not takes a strategy to fully validate drug binders, but just the these binders for hits/leads generation and its assay development
	-	Hit compounds are screened against target(s) and/or derivatives from the original drug are used to assess the target candidates (Chemical genomics approach)
	-	Target Information is also used for lead optimization from hit compound and/or the original drug

The selection of bait compounds is a key for reverse targeting approach and the Company uses several criteria for selections. The Company already selected bait drugs among inflammatory, respiratory and diabetes fields and identified its binders.